This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Erickson, D. Articles by Young, W. F. Search for Related Content PubMed PubMed Citation Articles by Erickson, D. Articles by Young, W. F., Jr.

Benign Paragangliomas: Clinical Presentation and Treatment Outcomes in 236 Patients

Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (D.E., Y.C.K., W.F.Y.), Department of Neurosurgery (M.J.E.), and Department of Surgery (G.B.T., C.S.G., J.A.v.H.), Mayo Clinic, and Mayo Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: William F. Young, Jr., M.D., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. E-mail: Young.William{at}mayo.edu

Abstract

Paragangliomas are rare tumors that arise from extraadrenal chromaffin cells. We examined the clinical characteristics, location, treatment, and outcome of 236 patients (141 females, 60%) with 297 benign paragangliomas evaluated at the Mayo Clinic during 1978–1998. The mean age (±SD) at diagnosis was 47 ± 16 yr. Of the 297 paragangliomas, 205 were in the head and neck region, and 92 were below the neck. Paragangliomas were discovered and diagnosed incidentally on imaging studies in 9% of patients. Biochemical screening was performed in 128 patients; 40 patients (17% of the total and 31% of those screened) had hyperfunctional tumors. Of the 40 patients with tumoral catecholamine excess, 38 had documented hypertension. In patients identified with catecholamine-secreting paragangliomas, the sensitivities achieved by measurements in the 24-h urine collection were 74% for total metanephrines, 84% for norepinephrine, 18% for dopamine, and 14% for epinephrine. Multiple imaging modalities were used for tumor localization. The false negative rates were 0% for magnetic resonance imaging, 5.8% for computed tomography, 3.4% for angiography, 10.7% for ultrasonography, and 39% for radioactive iodine-labeled metaiodobenzylguanidine scintigraphy. Of 192 patients (81.4%) with follow-up data (mean, 43.9 months; range, 0.5–240), operative cure was achieved in 133 (69%). Of the 59 patients without cure, 23 had persistent disease, 5 had recurrent disease, 16 had multiple persistent synchronous tumors, and 15 subsequently developed metachronous tumors. In conclusion, most paragangliomas are nonhypersecretory and located in the head and neck region. Magnetic resonance imaging was associated with the lowest false negative rate, and metaiodobenzylguanidine was the least sensitive imaging study. A significant proportion of patients (31%) has persistent or recurrent disease, and long-term follow-up is important.

This article has been cited by other articles:

				M. Procopiou, H. Finney, S. A Akker, S. L Chew, W. M Drake, J. Burrin, and A. B Grossman Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors Eur. J. Endocrinol., July 1, 2009; 161(1): 131 - 140. [Abstract] [Full Text] [PDF]

				H. J L M Timmers, A.-P. Gimenez-Roqueplo, M. Mannelli, and K. Pacak Clinical aspects of SDHx-related pheochromocytoma and paraganglioma Endocr. Relat. Cancer, June 1, 2009; 16(2): 391 - 400. [Abstract] [Full Text] [PDF]

				B Havekes, A A van der Klaauw, M M Weiss, J C Jansen, A G L van der Mey, A H J T Vriends, B A Bonsing, J A Romijn, and E P M Corssmit Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas Endocr. Relat. Cancer, June 1, 2009; 16(2): 527 - 536. [Abstract] [Full Text] [PDF]

				N. M. Hahn, M. Reckova, L. Cheng, L. A. Baldridge, O. W. Cummings, and C. J. Sweeney Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate J. Clin. Oncol., January 20, 2009; 27(3): 460 - 463. [Full Text] [PDF]

				H. J. L. M. Timmers, K. Pacak, T. T. Huynh, M. Abu-Asab, M. Tsokos, M. J. Merino, B. E. Baysal, K. T. Adams, and G. Eisenhofer Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the Succinate Dehydrogenase Subunit B Gene J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4826 - 4832. [Abstract] [Full Text] [PDF]

				R Armstrong, M Sridhar, K L Greenhalgh, L Howell, C Jones, C Landes, J L McPartland, C Moores, P D Losty, and M Didi Phaeochromocytoma in children Arch. Dis. Child., October 1, 2008; 93(10): 899 - 904. [Abstract] [Full Text] [PDF]

				K. P. Koopmans, P. L. Jager, I. P. Kema, M. N. Kerstens, F. Albers, and R. P.F. Dullaart 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas J. Nucl. Med., August 1, 2008; 49(8): 1232 - 1237. [Abstract] [Full Text] [PDF]

				A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]

				K. Y. Lee, Y.-W. Oh, H. J. Noh, Y. J. Lee, H.-S. Yong, E.-Y. Kang, K. A. Kim, and N. J. Lee Extraadrenal paragangliomas of the body: imaging features. Am. J. Roentgenol., August 1, 2006; 187(2): 492 - 504. [Abstract] [Full Text] [PDF]

				W. F. Young Jr and A. L. Abboud Paraganglioma--all in the family. J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 790 - 792. [Full Text] [PDF]

				G. Eisenhofer, D. S. Goldstein, P. Sullivan, G. Csako, F. M. Brouwers, E. W. Lai, K. T. Adams, and K. Pacak Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2068 - 2075. [Abstract] [Full Text] [PDF]

				D. G. Abud, C. Mounayer, G. Benndorf, M. Piotin, L. Spelle, and J. Moret Intratumoral Injection of Cyanoacrylate Glue in Head and Neck Paragangliomas AJNR Am. J. Neuroradiol., October 1, 2004; 25(9): 1457 - 1462. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				N. W. W. Choong and J. M. Miles Bilateral Carotid Body Paraganglioma Mayo Clin. Proc., May 1, 2004; 79(5): 681 - 681. [PDF]

				V. D. Garovic, M. C. Hogan, S. K. R. Kanakiriya, C. S. Grant, and W. F. Young Jr Labile hypertension, increased metanephrines and imaging misadventures Nephrol. Dial. Transplant., April 1, 2004; 19(4): 1004 - 1006. [Full Text] [PDF]

				D. P. Saurborn, J. B. Kruskal, I. E. Stillman, and S. Parangi Best Cases from the AFIP: Paraganglioma of the Organs of Zuckerkandl RadioGraphics, September 1, 2003; 23(5): 1279 - 1286. [Full Text] [PDF]

				A. L. Young, B. E. Baysal, A. Deb, and W. F. Young Jr. Familial Malignant Catecholamine-Secreting Paraganglioma with Prolonged Survival Associated with Mutation in the Succinate Dehydrogenase B Gene J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4101 - 4105. [Abstract] [Full Text] [PDF]

				B E Baysal Hereditary paraganglioma targets diverse paraganglia J. Med. Genet., September 1, 2002; 39(9): 617 - 622. [Abstract] [Full Text] [PDF]

				R. G. Dluhy Pheochromocytoma -- Death of an Axiom N. Engl. J. Med., May 9, 2002; 346(19): 1486 - 1488. [Full Text] [PDF]